Please read our Terms of Sale and confirm you agree before browsing this site.
All products sold on this website are intended strictly for laboratory and research purposes. They are not for human or animal consumption, use, or application in any form. By purchasing, the Buyer represents and warrants that they are a qualified researcher, laboratory, or institution acquiring these products solely for lawful, non-clinical research purposes, and that the products will not be introduced into the body of any human or animal.
No statement on this website, in product descriptions, or in any communication from Helix Collective constitutes medical advice or a claim that any product can diagnose, treat, cure, or prevent any disease or condition. These products have not been evaluated by any medicines regulatory authority for human use.
The Buyer acknowledges that they are solely responsible for determining the legality of purchasing, possessing, and using these products in their jurisdiction, and for complying with all applicable laws and institutional regulations. The Buyer assumes full responsibility and risk for any use of the products outside their labeled research purpose.
To the maximum extent permitted by law, Helix Collective shall not be liable for any indirect, incidental, special, consequential, or punitive damages, or loss of profits, arising from the purchase or use (or misuse) of any product. Helix Collective's total liability arising from any order shall not exceed the amount paid by the Buyer for the relevant product. Nothing in this clause limits liability that cannot lawfully be excluded, including liability for gross negligence, fraud, or death or personal injury caused by Helix Collective's negligence.
Except as expressly stated, all products are sold "as is" without warranties of any kind, whether express or implied, including implied warranties of merchantability or fitness for a particular purpose.
The Buyer agrees to indemnify and hold harmless Helix Collective, its officers, employees, and agents from any claims, damages, or expenses (including legal fees) arising from the Buyer's misuse of any product or breach of these Terms.
By purchasing from this website, the Buyer confirms that they are at least 18 years of age and have the legal capacity to enter into this agreement.
The Buyer is solely responsible for ensuring that the purchase, import, possession, and use of these products complies with all applicable local, national, and international laws.
This Agreement shall be governed by and construed in accordance with the laws of the Republic of South Africa.
If any provision of these Terms is found unenforceable, the remaining provisions shall remain in full force and effect.
Retatrutide (LY-3437943) is the most potent weight loss research compound to emerge from clinical trials to date. A triple GLP-1/GIP/glucagon receptor agonist developed by Eli Lilly, it produced an average 24.2% body weight reduction in a landmark Phase 2 trial published in the New England Journal of Medicine. Here is everything the science shows — and where to buy Retatrutide in South Africa.
Retatrutide (INN: retatrutide; development code: LY-3437943) is a novel once-weekly injectable investigational compound developed by Eli Lilly and Company. Unlike existing GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro), which target one or two receptors respectively, Retatrutide simultaneously activates three hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor.
This triple mechanism gives Retatrutide a uniquely comprehensive metabolic action — suppressing appetite through GLP-1 and GIP pathways while simultaneously increasing energy expenditure via glucagon receptor activation. The result, as the 2023 Phase 2 trial demonstrated, is a magnitude of weight loss that significantly exceeds any previously studied or approved compound.
338 adults with obesity (BMI ≥30) randomised to once-weekly Retatrutide or placebo. At the highest dose (12mg), participants achieved a mean weight reduction of 24.2% from baseline at 48 weeks — the greatest weight loss ever recorded in a clinical trial for an anti-obesity medication.
Read on NEJM →Weight loss was clearly dose-dependent: 4mg group achieved 8.7% reduction, 8mg group achieved 17.3%, and 12mg group achieved 24.2% — all significantly greater than placebo (2.1%). Weight loss was still accelerating at 48 weeks, suggesting greater reductions may be possible with longer treatment.
Read on NEJM →Beyond weight loss, participants showed significant improvements in waist circumference, fasting insulin levels, HbA1c, blood pressure, and triglycerides — demonstrating broad cardiometabolic benefit beyond weight reduction alone.
Read on NEJM →Retatrutide is currently in Phase 3 clinical trials (TRIUMPH programme) evaluating long-term efficacy and safety in obesity, type 2 diabetes, and MASH (metabolic dysfunction-associated steatohepatitis) across multiple global sites.
View on ClinicalTrials.gov →In a randomised trial for metabolic dysfunction-associated steatotic liver disease, Retatrutide produced substantial reductions in liver fat content alongside significant weight loss, supporting its potential beyond obesity into metabolic liver disease.
Read on Nature Medicine →A pooled analysis of randomised controlled trials confirmed the efficacy and safety of Retatrutide as a GLP-1, GIP, and glucagon receptor agonist for obesity treatment across the studied dose range.
Read on PMC →The most common side effects reported in the NEJM Phase 2 trial were gastrointestinal in nature and consistent with the GLP-1 class:
Retatrutide 30mg currently on special at R1,500 (normal R1,700). 99% purity, COA available, bacwater included. Fast nationwide delivery across South Africa from Helix Collective SA.